This research has paved the way for the use of FASN inhibitors such as TVB-2640 in clinical trials in combination with trastuzumab in HER2 metastatic BC pretreated with anti-HER2 drugs (NCT03179904, currently ongoing). Here, FASN is linked to breast cancer.